Galmed Pharmaceuticals Lt... (GLMD)
NASDAQ: GLMD
· Real-Time Price · USD
1.43
-0.05 (-3.38%)
At close: Aug 15, 2025, 3:59 PM
1.47
3.14%
After-hours: Aug 15, 2025, 07:58 PM EDT
Galmed Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | 9K | 6K | 17K | 9K | 8K | 9K | n/a | n/a | 9K | 10K | 11K | 10K | 11K |
Gross Profit | n/a | n/a | n/a | -74K | -9K | -6K | -17K | -9K | -8K | -9K | n/a | n/a | -9K | -10K | -11K | -10K | -11K |
Operating Income | -1.26M | -1.56M | -2.01M | -1.22M | -1.4M | -2.15M | -1.47M | -1.87M | -2M | -2.45M | -5.38M | -3.73M | -6.09M | -7.45M | -7.84M | -8.41M | -9.13M |
Interest Income | n/a | n/a | n/a | 103K | 126K | 135K | n/a | 278K | 172K | 752.00 | 30K | n/a | n/a | 188K | 131K | 16K | 227K |
Pretax Income | -1.1M | -3.21M | -1.91M | -1.12M | -1.27M | -2.02M | -1.47M | -1.59M | -1.83M | -2.64M | -5.35M | -3.73M | -6.14M | -7.45M | -7.71M | -8.4M | -8.9M |
Net Income | -1.1M | -3.21M | -1.91M | -1.12M | -1.27M | -2.02M | -1.47M | -1.59M | -1.66M | -2.83M | -5.38M | -3.73M | -6.19M | -7.45M | -7.71M | -8.4M | -8.9M |
Selling & General & Admin | 630K | 572K | 1.27M | 688K | 757K | 1.02M | 912K | 1.06M | 919K | 1.07M | 1.14M | 1.15M | 1.3M | 1.23M | 1.3M | 1.38M | 1.75M |
Research & Development | 634K | 1.07M | 738K | 534K | 635K | 1.12M | 556K | 809K | 1.08M | 1.38M | 4.24M | 2.58M | 4.8M | 6.26M | 6.54M | 7.04M | 7.38M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | 556K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 1.26M | 1.64M | 2.01M | 1.22M | 1.39M | 2.15M | 1.47M | 1.87M | 2M | 2.45M | 5.38M | 3.73M | 6.09M | 7.49M | 7.84M | 8.41M | 9.13M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | 5K | n/a | n/a | 190K | 30K | 4K | 51K | 43K | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | -9K | -6K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 1.26M | 1.64M | 2.01M | 1.22M | 1.4M | 2.15M | 1.47M | 1.87M | 2M | 2.45M | 5.38M | 3.73M | 6.09M | 7.49M | 7.84M | 8.41M | 9.13M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | -37.81K | n/a | n/a | -172K | 190K | 30K | -4K | 51K | -40K | n/a | n/a | n/a |
Shares Outstanding (Basic) | 1.78M | 1.61M | 69.13K | 524.56K | 5.46M | 5.05M | 6.25M | 1.68M | 1.68M | 1.68M | 1.68M | 1.67M | 1.67M | 1.67M | 1.67M | 1.67M | 1.56M |
Shares Outstanding (Diluted) | 1.78M | 1.61M | 69.13K | 524.56K | 5.46M | 5.05M | 6.25M | 1.68M | 1.68M | 1.68M | 1.68M | 1.67M | 1.67M | 1.67M | 1.67M | 1.67M | 1.56M |
EPS (Basic) | -0.62 | -46.42 | -27.69 | -2.13 | -0.23 | -0.4 | -0.24 | -0.95 | -0.99 | -1.68 | -3.2 | -2.23 | -3.7 | -4.46 | -4.61 | -5.02 | -5.71 |
EPS (Diluted) | -0.62 | -46.42 | -27.69 | -2.13 | -0.23 | -0.4 | -0.24 | -0.95 | -0.99 | -1.68 | -3.2 | -2.23 | -3.7 | -4.45 | -4.61 | -5.02 | -5.71 |
EBITDA | -1.26M | -1.64M | -2.01M | -1.15M | -1.39M | -2.15M | -1.46M | -1.86M | -1.99M | -2.44M | -5.37M | -3.72M | -6.08M | -7.48M | -7.83M | -8.4M | -9.12M |
EBIT | -1.26M | -3.21M | -2.01M | -1.22M | -1.4M | -2.15M | -1.47M | -1.87M | -2M | -2.45M | -5.38M | -3.73M | -6.09M | -7.49M | -7.84M | -8.41M | -9.13M |
Depreciation & Amortization | n/a | 1.56M | n/a | 74K | 9K | 6K | 17K | 9K | 8K | 9K | 8K | 9K | 9K | 10K | 11K | 10K | 11K |